QUIDELORTHO CORP
QDELNASDAQTrading Snapshot
- Day Range
- $13.63 β $14.26
- 52-Week Range
- $9.92 β $35.58
- Volume (shares)
- 1,508,989
- Avg Volume (shares)
- β
- Shares Outstanding
- 68.6M
- Next Earnings
- 2026-11-03
Fundamentals Snapshot
- Annual Revenue
- $2.73B
- Last Q Revenue
- $631M
- P/E Ratio
- -0.9
- P/S Ratio
- 0.4x
- EPS (TTM)
- $-15.35
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.9%
QUIDELORTHO CORP
QDELAbout QUIDELORTHO CORP
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Transforming Data Into Actionable Insights in the Lab
SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and

QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)Β ("QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will issue a press release to report its financi

Financial Analysis: Elutia (NASDAQ:ELUT) & QuidelOrtho (NASDAQ:QDEL)
QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Elutia (NASDAQ: ELUT - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength

QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board o

Reasons to Add QuidelOrtho Stock to Your Portfolio for Now
QDEL's strong Q2 results, diversified product portfolio and cost-saving initiatives bolster its growth prospects despite persistent weakness in respiratory demand.

Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p